ALK and non-small cell lung carcinoma: In retrospective studies of ALK-positive advanced NSCLC, ceritinib demonstrated a longer median PFS compared to crizotinib for first-line treatment [80], and a second-generation ALK inhibitor, alectinib demonstrated a lower incidence of CNS progression and a tendency toward superior PFS compared to ceretinib in specific patients who had progressed on crizotinib [81].